Although the plethora of breast cancer biomarkers is steadily increasing, we believe we are the first to report on a biomarker that can aid clinicians in their decision-making process regarding the administration of trastuzumab therapy to ER-negative/Her2-positive breast cancer patients. The gene discussed is ERBB2; the disease is breast carcinoma.